Teva Pharmaceutical Industries Ltd. has announced that it would purchase Allergan PLC’s generic pharmaceuticals distributor for $500 million, just a day after Teva closed its much larger deal to buy Allergan’s generics business.
Teva is buying Allergan’s Anda Inc., the fourth-largest distributor of generic pharmaceuticals in the U.S.
Anda distributes drugs from more than 300 manufacturers to pharmacies across the U.S. and in 2016 Anda is expected to generate more than $1 billion in third-party net revenue.
As part of the deal, Teva will acquire distribution centers in Mississippi, Florida, and Ohio. Anda will operate as a stand-alone business. The deal is subject to regulatory approval and other closing conditions and is expected to close in the second half of the year.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas